Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Carcinoma, Transitional Cell"" wg kryterium: Temat


Tytuł:
MRI for risk stratification of muscle invasion by upper tract urothelial carcinoma: a feasibility study.
Autorzy:
Messina E; Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy.
Proietti F; Department of Maternal-Infant and Urological Sciences, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy.; Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy.
Laschena L; Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy.
Flammia RS; Department of Maternal-Infant and Urological Sciences, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy.; Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy.
Pecoraro M; Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy.
Cipollari S; Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy.
Simone G; Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy.
Catalano C; Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy.
Leonardo C; Department of Maternal-Infant and Urological Sciences, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy.; Department of Urology, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy.
Panebianco V; Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale del Policlinico 155, Rome, 00185, Italy. .; Department of Radiological Sciences, Oncology and Pathology, Sapienza University/Policlinico Umberto I, Viale Regina Elena 324, Rome, 00161, Italy. .
Pokaż więcej
Źródło:
European radiology experimental [Eur Radiol Exp] 2024 Jan 19; Vol. 8 (1), pp. 9. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/diagnostic imaging
Carcinoma, Transitional Cell*/diagnostic imaging
Carcinoma, Transitional Cell*/pathology
Humans ; Feasibility Studies ; Magnetic Resonance Imaging ; Muscles/pathology ; Risk Assessment
Czasopismo naukowe
Tytuł:
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Autorzy:
Galsky MD; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: .
Guan X; Genentech Inc., South San Francisco, CA 94080, USA.
Rishipathak D; Genentech Inc., South San Francisco, CA 94080, USA.
Rapaport AS; Genentech Inc., South San Francisco, CA 94080, USA.
Shehata HM; Genentech Inc., South San Francisco, CA 94080, USA.
Banchereau R; Genentech Inc., South San Francisco, CA 94080, USA.
Yuen K; Genentech Inc., South San Francisco, CA 94080, USA.
Varfolomeev E; Genentech Inc., South San Francisco, CA 94080, USA.
Hu R; Genentech Inc., South San Francisco, CA 94080, USA.
Han CJ; Genentech Inc., South San Francisco, CA 94080, USA.
Li H; Hoffmann-La Roche Ltd, Mississauga, ON, Canada.
Liang Y; Genentech Inc., South San Francisco, CA 94080, USA.
Vucic D; Genentech Inc., South San Francisco, CA 94080, USA.
Wang L; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; GeneDx, Stamford, CT, USA.
Zhu J; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; GeneDx, Stamford, CT, USA.
Yu H; GeneDx, Stamford, CT, USA.
Herbst RH; Immunai, New York, NY, USA.
Hajaj E; Immunai, New York, NY, USA.
Kiner E; Immunai, New York, NY, USA.
Bamias A; National and Kapodistrian University of Athens, Athens, Greece.
De Santis M; Department of Urology, Charité - Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
Davis ID; Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
Arranz JÁ; Gregorio Marañón General University Hospital, Madrid, Spain.
Kikuchi E; St. Marianna University School of Medicine, Kawasaki, Japan.
Bernhard S; Roche Products Ltd, Welwyn Garden City, UK.
Williams P; Genentech Inc., South San Francisco, CA 94080, USA.
Lee C; Roche Products Ltd, Welwyn Garden City, UK.
Mellman I; Genentech Inc., South San Francisco, CA 94080, USA.
Sanjabi S; Genentech Inc., South San Francisco, CA 94080, USA.
Johnston R; Genentech Inc., South San Francisco, CA 94080, USA.
Black PC; Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
Grande E; MD Anderson Cancer Center Madrid, Madrid, Spain.
Mariathasan S; Genentech Inc., South San Francisco, CA 94080, USA. Electronic address: .
Pokaż więcej
Źródło:
Cell reports. Medicine [Cell Rep Med] 2024 Feb 20; Vol. 5 (2), pp. 101393. Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:
Journal Article
MeSH Terms:
Urologic Neoplasms*/drug therapy
Urologic Neoplasms*/chemically induced
Urologic Neoplasms*/pathology
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/chemically induced
Carcinoma, Transitional Cell*/pathology
Antibodies, Monoclonal, Humanized*
Humans ; Cisplatin/therapeutic use ; Carboplatin/therapeutic use ; Gemcitabine ; Deoxycytidine/therapeutic use
Czasopismo naukowe
Tytuł:
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Autorzy:
Rijnders M; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Nakauma-González JA; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Cancer Computational Biology Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Robbrecht DGJ; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Gil-Jimenez A; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.
Balcioglu HE; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Oostvogels AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Aarts MJB; Department of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands.
Boormans JL; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Hamberg P; Department of Medical Oncology, Franciscus Gasthuis & Vlietland Hospital, Rotterdam/Schiedam, The Netherlands.
van der Heijden MS; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Szabados BE; Barts Cancer Institute, Queen Mary University of London, London, UK.
van Leenders GJLH; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Voortman J; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Westgeest HM; Department of Internal Medicine, Amphia Hospital Breda, Breda, The Netherlands.
de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
van der Veldt AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Department of Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Debets R; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. .
Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Amgen Inc., Breda, The Netherlands.
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Feb 14; Vol. 15 (1), pp. 1349. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/genetics
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Prospective Studies ; T-Lymphocytes ; B7-H1 Antigen
Czasopismo naukowe
Tytuł:
The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
Autorzy:
Zhang J; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yang M; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wei D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhang D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chen Z; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .
Zhu H; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 13; Vol. 24 (1), pp. 202. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/surgery
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Antibodies, Monoclonal, Humanized*
Humans ; Cisplatin/therapeutic use ; Gemcitabine ; Retrospective Studies ; Deoxycytidine/adverse effects ; Muscles ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Presence, Subtypes, and Prognostic Significance of Tertiary Lymphoid Structures in Urothelial Carcinoma of the Bladder.
Autorzy:
Ma G; Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Jia H; Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Zhang G; Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Liang Y; Key Laboratory, Department of Urology and Andrology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Dong X; Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Fu G; Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Wang X; Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Niu H; Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Feb 02; Vol. 29 (2), pp. e248-e258.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/surgery
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/pathology
Tertiary Lymphoid Structures*/pathology
Non-Muscle Invasive Bladder Neoplasms*
Humans ; Prognosis ; Urinary Bladder/surgery ; Urinary Bladder/pathology ; Lymphocytes, Tumor-Infiltrating/pathology
Czasopismo naukowe
Tytuł:
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Autorzy:
Powles T; Barts Cancer Institute, Queen Mary University of London ECMC, Barts Health, London, UK. Electronic address: .
Assaf ZJ; Roche/Genentech, South San Francisco, CA, USA.
Degaonkar V; Roche/Genentech, South San Francisco, CA, USA.
Grivas P; University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA.
Hussain M; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Oudard S; Georges Pompidou European Hospital, University of Paris, Paris, France.
Gschwend JE; Department of Urology, Rechts der Isar Medical Center, Technical University Munich, Munich, Germany.
Albers P; Department of Urology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Castellano D; Medical Oncology Department CIBER-ONC, University Hospital 12 de Octubre, Madrid, Spain.
Nishiyama H; Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Daneshmand S; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Sharma S; Natera, Inc, San Carlos, CA, USA.
Sethi H; Natera, Inc, San Carlos, CA, USA.
Aleshin A; Natera, Inc, San Carlos, CA, USA.
Shi Y; Roche/Genentech, South San Francisco, CA, USA.
Davarpanah N; Roche/Genentech, South San Francisco, CA, USA.
Carter C; Roche/Genentech, South San Francisco, CA, USA.
Bellmunt J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mariathasan S; Roche/Genentech, South San Francisco, CA, USA.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2024 Feb; Vol. 85 (2), pp. 114-122. Date of Electronic Publication: 2023 Jul 26.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/pathology
Circulating Tumor DNA*/genetics
Urinary Bladder Neoplasms*
Antibodies, Monoclonal, Humanized*
Humans ; Prospective Studies ; Treatment Outcome ; Neoplasm Recurrence, Local ; Adjuvants, Immunologic/therapeutic use ; Muscles/pathology ; Recurrence ; Antineoplastic Combined Chemotherapy Protocols
Czasopismo naukowe
Tytuł:
Xanthogranulomatous Ureteritis: A Diagnostic Challenge in a Patient with Bladder Cancer.
Autorzy:
Nova-Camacho LM; Department of Pathology, Donostia University Hospital, San Sebastian, Spain.
Val-Carreres Castellote A; Department of Pathology, Donostia University Hospital, San Sebastian, Spain.
Villafruela Mateos A; Department of Urology, Donostia University Hospital, San Sebastian, Spain.
Pokaż więcej
Źródło:
International journal of surgical pathology [Int J Surg Pathol] 2024 Feb; Vol. 32 (1), pp. 182-186. Date of Electronic Publication: 2023 May 04.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/complications
Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/surgery
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/pathology
Ureter*/surgery
Ureter*/pathology
Urinary Tract Infections*/pathology
Gastrointestinal Diseases*/pathology
Male ; Humans ; Middle Aged ; Inflammation/pathology ; Granuloma/pathology ; Plasma Cells/pathology
Czasopismo naukowe
Tytuł:
Do Urine Cytology and FISH Analysis Have a Role in the Follow-Up Protocol of Upper Tract Urothelial Carcinoma?
Autorzy:
Carmona O; The Department of Urology, Sheba Medical Center, Ramat Gan, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: .
Kleinmann N; The Department of Urology, Sheba Medical Center, Ramat Gan, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Zilberman DE; The Department of Urology, Sheba Medical Center, Ramat Gan, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dotan ZA; The Department of Urology, Sheba Medical Center, Ramat Gan, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shvero A; The Department of Urology, Sheba Medical Center, Ramat Gan, Israel; The School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pokaż więcej
Źródło:
Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Feb; Vol. 22 (1), pp. 98-105. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/pathology
Humans ; Retrospective Studies ; Follow-Up Studies ; Cytodiagnosis
Czasopismo naukowe
Tytuł:
Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features.
Autorzy:
Oliver-Krasinski JM; From the Department of Pathology, Montefiore Medical Center, Bronx, New York (Oliver-Krasinski).
Bidot S; the Department of Pathology, Emory University School of Medicine, Atlanta, Georgia (Bidot, Tinsley, Harik).
Ingram JW; the Department of Urology, Columbia University Irving Medical Center, New York, New York (Ingram, McKiernan).
O'Toole KM; the Department of Pathology and Cell Biology, Columbia University, New York, New York (O'Toole).
McKiernan JM; the Department of Urology, Columbia University Irving Medical Center, New York, New York (Ingram, McKiernan).
Tinsley M; the Department of Pathology, Emory University School of Medicine, Atlanta, Georgia (Bidot, Tinsley, Harik).
Harik LR; the Department of Pathology, Emory University School of Medicine, Atlanta, Georgia (Bidot, Tinsley, Harik).
Pokaż więcej
Źródło:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2024 Feb 01; Vol. 148 (2), pp. 223-229.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/therapy
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/therapy
Carcinoma, Transitional Cell*/pathology
Carcinoma in Situ*
Humans ; Urinary Bladder/pathology ; Prognosis
Czasopismo naukowe
Tytuł:
Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study.
Autorzy:
Knapp DW; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA; Purdue Institute for Cancer Research, Purdue University, 201 S. University St., West Lafayette, IN 47907, USA. Electronic address: .
Dhawan D; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
Ruple A; Purdue Institute for Cancer Research, Purdue University, 201 S. University St., West Lafayette, IN 47907, USA; Department of Public Health, College of Health and Human Sciences, Purdue University, 700 W. State St., West Lafayette, IN 47907, USA.
Cooper BR; Bindley Bioscience Center, Purdue University, 1203 W. State St., West Lafayette, IN 47907, USA.
Zhang M; Purdue Institute for Cancer Research, Purdue University, 201 S. University St., West Lafayette, IN 47907, USA; Department of Statistics, College of Science, Purdue University, 150 N. University St., West Lafayette, IN 47907, USA.
Liu D; Department of Statistics, College of Science, Purdue University, 150 N. University St., West Lafayette, IN 47907, USA.
Ramos-Vara JA; Purdue Institute for Cancer Research, Purdue University, 201 S. University St., West Lafayette, IN 47907, USA; Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, 725 Harrison St., West Lafayette, IN 47907, USA.
Bonney PL; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
Fourez LM; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
Enstrom AW; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
Lahrman SA; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
Tullius JA; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
Pokaż więcej
Źródło:
Veterinary journal (London, England : 1997) [Vet J] 2024 Feb; Vol. 303, pp. 106044. Date of Electronic Publication: 2023 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/epidemiology
Urinary Bladder Neoplasms*/etiology
Urinary Bladder Neoplasms*/veterinary
Carcinoma, Transitional Cell*/epidemiology
Carcinoma, Transitional Cell*/etiology
Carcinoma, Transitional Cell*/veterinary
Cigarette Smoking*
Dog Diseases*/epidemiology
Dog Diseases*/etiology
Dogs ; Animals ; Cohort Studies ; Cotinine ; Scotland/epidemiology
Czasopismo naukowe
Tytuł:
Development and Validation of a Preoperative Nomogram for Endoscopic Management Decision Making in Upper Urinary Tract Urothelial Carcinoma.
Autorzy:
Nakamoto T; Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.; Department of Pathology, Kansai Medical University Hospital, Osaka, Japan.
Yoshida T; Department of Urology and Andrology, Kansai Medical University, Osaka, Japan. .; Corporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, Japan. .; Faculty of Engineering, Tottori University Graduate School of Engineering, Tottori, Japan. .
Katayama S; Department of Urology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Ohe C; Department of Pathology, Kansai Medical University Hospital, Osaka, Japan.; Corporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, Japan.
Kawaura T; Department of Mathematics, Kansai Medical University, Osaka, Japan.
Horii S; Department of Urology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Ikeda J; Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Kono Y; Department of Radiology, Kansai Medical University, Osaka, Japan.
Murota T; Department of Urology and Andrology, General Medical Center, Kansai Medical University, Osaka, Japan.
Kitawaki T; Department of Mathematics, Kansai Medical University, Osaka, Japan.
Araki M; Department of Urology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Kinoshita H; Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Pokaż więcej
Źródło:
Annals of surgical oncology [Ann Surg Oncol] 2024 Feb; Vol. 31 (2), pp. 1393-1401. Date of Electronic Publication: 2023 Nov 05.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*
Ureteral Neoplasms*
Kidney Neoplasms*
Urinary Tract*/pathology
Humans ; Nomograms ; Retrospective Studies ; Decision Making
Czasopismo naukowe
Tytuł:
Secondary tumours in orthotopic neobladder using isolated gut segment post radical cystectomy for urothelial carcinoma: a systematic review.
Autorzy:
Bahadori A; Redcliffe Hospital, Redcliffe, QLD, 4020, Australia. .
Bray G; Redcliffe Hospital, Redcliffe, QLD, 4020, Australia.
Rukin N; Redcliffe Hospital, Redcliffe, QLD, 4020, Australia.
Pokaż więcej
Źródło:
International urology and nephrology [Int Urol Nephrol] 2024 Feb; Vol. 56 (2), pp. 519-525. Date of Electronic Publication: 2023 Sep 21.
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/pathology
Urinary Diversion*
Neoplasms, Second Primary*/pathology
Male ; Humans ; Cystectomy ; Urinary Bladder/pathology
Czasopismo naukowe
Tytuł:
Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries.
Autorzy:
Milloy N; Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, Cheshire, United Kingdom.
Kirker M; Pfizer, New York, NY.
Unsworth M; Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, Cheshire, United Kingdom. Electronic address: .
Montgomery R; Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, Cheshire, United Kingdom.
Kluth C; Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, Cheshire, United Kingdom.
Kearney M; The healthcare business of Merck Healthcare KGaA, Darmstadt, Germany.
Chang J; Pfizer, New York, NY.
Pokaż więcej
Źródło:
Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Feb; Vol. 22 (1), pp. e136-e147.e1. Date of Electronic Publication: 2023 Oct 02.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents*/pharmacology
Humans ; Platinum/therapeutic use ; Cross-Sectional Studies ; Europe
Czasopismo naukowe
Tytuł:
ASO Visual Abstract: Development and Validation of a Preoperative Nomogram for Endoscopic Management Decision Making in Upper Urinary Tract Urothelial Carcinoma.
Autorzy:
Nakamoto T; Department of Urology and Andrology, Kansai Medical University, General Medical Center, Osaka, Japan.; Department of Pathology, Kansai Medical University Hospital, Osaka, Japan.
Yoshida T; Department of Urology and Andrology, Kansai Medical University, General Medical Center, Osaka, Japan. .; Corporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, Japan. .; Faculty of Engineering, Tottori University Graduate School of Engineering, Tottori, Japan. .
Katayama S; Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Ohe C; Department of Pathology, Kansai Medical University Hospital, Osaka, Japan.; Corporate Sponsored Research Programs for Multicellular Interactions in Cancer, Kansai Medical University, Osaka, Japan.
Kawaura T; Department of Mathematics, Kansai Medical University, Osaka, Japan.
Horii S; Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Ikeda J; Department of Urology and Andrology, Kansai Medical University, General Medical Center, Osaka, Japan.
Kono Y; Department of Radiology, Kansai Medical University, Osaka, Japan.
Murota T; Department of Urology and Andrology, Kansai Medical University, General Medical Center, Osaka, Japan.
Kitawaki T; Department of Mathematics, Kansai Medical University, Osaka, Japan.
Araki M; Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Kinoshita H; Department of Urology and Andrology, Kansai Medical University, General Medical Center, Osaka, Japan.
Pokaż więcej
Źródło:
Annals of surgical oncology [Ann Surg Oncol] 2024 Feb; Vol. 31 (2), pp. 1416-1417.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*
Kidney Neoplasms*/surgery
Ureteral Neoplasms*/surgery
Urinary Tract*/pathology
Humans ; Nomograms ; Decision Making ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy.
Autorzy:
Rac G; Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
Patel HD; Department of Urology, Loyola University Medical Center, Maywood, IL, USA.; Department of Urology, Fienberg School of Medicine, Northwestern University, Evanston, IL, USA.
James C; Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
Desai S; Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
Caruso VM; Convergent Genomics, Inc., South San Francisco, CA, USA.
Fischer DS; Convergent Genomics, Inc., South San Francisco, CA, USA.
Lentz PS; Convergent Genomics, Inc., South San Francisco, CA, USA.
Ward CT; Convergent Genomics, Inc., South San Francisco, CA, USA.
Mazzarella BC; Convergent Genomics, Inc., South San Francisco, CA, USA.
Phillips KG; Convergent Genomics, Inc., South San Francisco, CA, USA.
Doshi C; Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
Bicocca VT; Convergent Genomics, Inc., South San Francisco, CA, USA.
Levin TG; Convergent Genomics, Inc., South San Francisco, CA, USA.
Wolfe AJ; Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.
Gupta GN; Department of Urology, Loyola University Medical Center, Maywood, IL, USA.; Department of Radiology, Loyola University Medical Center, Maywood, IL, USA.; Department of Surgery, Loyola University Medical Center, Maywood, IL, USA.
Pokaż więcej
Źródło:
Molecular oncology [Mol Oncol] 2024 Feb; Vol. 18 (2), pp. 291-304. Date of Electronic Publication: 2023 Oct 05.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Humans ; Cohort Studies ; Administration, Intravesical ; Genomics ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Invasiveness/pathology ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
Autorzy:
Tamura D; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.
Abe M; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.; Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan.
Hiraki H; Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan.
Sasaki N; Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan.
Yashima-Abo A; Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan.
Ikarashi D; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.
Kato R; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.
Kato Y; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.
Maekawa S; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.
Kanehira M; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.
Takata R; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.
Maejima K; Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Sasagawa S; Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Fujita M; Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Suzuki Y; Department of Computational Biology and Medical Sciences, The University of Tokyo, Kashiwa, Japan.
Nakagawa H; Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Iwaya T; Department of Clinical Oncology, Iwate Medical University School of Medicine, Yahaba, Japan.
Nishizuka SS; Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan.
Obara W; Department of Urology, Iwate Medical University School of Medicine, Yahaba, Japan.
Pokaż więcej
Źródło:
Cancer science [Cancer Sci] 2024 Feb; Vol. 115 (2), pp. 529-539. Date of Electronic Publication: 2023 Dec 11.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/surgery
Circulating Tumor DNA*/genetics
Humans ; Prospective Studies ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Biomarkers ; Biomarkers, Tumor/genetics
Czasopismo naukowe
Tytuł:
Application of contrast-enhanced ultrasound in diagnosis and grading of bladder urothelial carcinoma.
Autorzy:
Zhang HP; Department of Ultrasound, Fujian Medical University Union Hospital, Antai Street & Xin Quan Road 29, Fuzhou, Fujian Province, China.
Liang RX; Department of Ultrasound, Fujian Medical University Union Hospital, Antai Street & Xin Quan Road 29, Fuzhou, Fujian Province, China.
Lin XY; Department of Ultrasound, Fujian Medical University Union Hospital, Antai Street & Xin Quan Road 29, Fuzhou, Fujian Province, China.
Xue ES; Department of Ultrasound, Fujian Medical University Union Hospital, Antai Street & Xin Quan Road 29, Fuzhou, Fujian Province, China.
Ye Q; Department of Ultrasound, Fujian Medical University Union Hospital, Antai Street & Xin Quan Road 29, Fuzhou, Fujian Province, China. .
Zhu YF; Department of Ultrasound, Fujian Medical University Union Hospital, Antai Street & Xin Quan Road 29, Fuzhou, Fujian Province, China.
Pokaż więcej
Źródło:
BMC medical imaging [BMC Med Imaging] 2024 Jan 25; Vol. 24 (1), pp. 26. Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/diagnostic imaging
Urinary Bladder Neoplasms*/surgery
Carcinoma, Transitional Cell*/diagnostic imaging
Carcinoma, Transitional Cell*/pathology
Humans ; Urinary Bladder/diagnostic imaging ; Contrast Media ; Diagnosis, Differential ; Ultrasonography
Czasopismo naukowe
Tytuł:
An accurate diagnostic approach for urothelial carcinomas based on novel dual methylated DNA markers in small-volume urine.
Autorzy:
Wu Y; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Cai D; Wuhan Ammunition Life-tech Company, Ltd., Wuhan, Hubei 430200, China.
Fan J; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Meng C; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
He S; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Li Z; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Zhang L; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Yang K; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Wang A; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Li X; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Du Y; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Xiong S; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Xia M; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Li T; Wuhan Ammunition Life-tech Company, Ltd., Wuhan, Hubei 430200, China.
Dong L; Wuhan Ammunition Life-tech Company, Ltd., Wuhan, Hubei 430200, China.
Gong Y; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Zhou L; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Li X; Department of Urology, Peking University First Hospital, Beijing 100034, China.; Institute of Urology, Peking University, Beijing 100034, China.; National Urological Cancer Center, Beijing 100034, China.; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing 100034, China.
Pokaż więcej
Źródło:
Chinese medical journal [Chin Med J (Engl)] 2024 Jan 20; Vol. 137 (2), pp. 232-234. Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/pathology
Humans ; Genetic Markers ; Biomarkers, Tumor/genetics ; Urothelium/pathology
Czasopismo naukowe
Tytuł:
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
Autorzy:
Okato A; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Utsumi T; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Ranieri M; Perlmutter Cancer Center, New York University, New York, New York, USA.
Zheng X; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Zhou M; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Pereira LD; Perlmutter Cancer Center, New York University, New York, New York, USA.
Chen T; Perlmutter Cancer Center, New York University, New York, New York, USA.
Kita Y; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Wu D; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Hyun H; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Lee H; Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, South Korea.
Gdowski AS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Raupp JD; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Clark-Garvey S; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Manocha U; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Chafitz A; Perlmutter Cancer Center, New York University, New York, New York, USA.
Sherman F; Perlmutter Cancer Center, New York University, New York, New York, USA.
Stephens J; Perlmutter Cancer Center, New York University, New York, New York, USA.
Rose TL; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Medicine.
Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Medicine.
Wobker SE; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Pathology and Laboratory Medicine.
Serody JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Medicine.; Department of Pathology and Laboratory Medicine.; Department of Microbiology and Immunology.
Damrauer JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Medicine.
Wong KK; Perlmutter Cancer Center, New York University, New York, New York, USA.
Kim WY; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Medicine.; Department of Genetics, and.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Pokaż więcej
Źródło:
The Journal of clinical investigation [J Clin Invest] 2024 Jan 16; Vol. 134 (2). Date of Electronic Publication: 2024 Jan 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/metabolism
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/metabolism
Animals ; Humans ; Mice ; Immunosuppression Therapy ; Receptor, Fibroblast Growth Factor, Type 3/genetics ; Receptor, Fibroblast Growth Factor, Type 3/metabolism
Czasopismo naukowe
Tytuł:
Plasmacytoid urothelial carcinoma with duodenal metastasis-A rare tumor with unusual site of metastasis with grim outcome.
Autorzy:
Chenniappan A; Department of Pathology (Histopathology Section), Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Stephen NS; Department of Pathology (Histopathology Section), Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Srinivas BH; Department of Pathology (Histopathology Section), Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Sreenivasan SK; Department of Urology and Renal Transplantation, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Govindarajalou R; Department of Radiodiagnosis, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Pokaż więcej
Źródło:
Indian journal of pathology & microbiology [Indian J Pathol Microbiol] 2024 Jan-Mar; Vol. 67 (1), pp. 175-177.
Typ publikacji:
Case Reports
MeSH Terms:
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/pathology
Plasmacytoma*
Humans ; Retrospective Studies ; Urinary Bladder/pathology ; Cystectomy/methods
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies